Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML
A multicenter, prospective, single-arm clinical study of veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG) in the treatment of elderly untreated acute myeloid leukemia (AML)
Acute Myeloid Leukemia
DRUG: veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG)
Event-free survival (EFS), Defined as the time interval from treatment initiation to the occurrence of induction failure, relapse, or death, whichever came first., Up to 60 months
Complete Remission (CR) rate, The percent of participants with complete remission (CR) was defined in accordance with the IWG Response Criteria in AML., Up to 60 months|Overall Survival (OS), OS will be measured from the date of registration to the date of the event (i.e., death) or the date of last follow-up to evaluate that event. Patients who are event-free at their last follow-up evaluation will be censored at that time point., Up to 60 months|Overall Response Rate (ORR), Defined as the percentage of participants achieving a best overall response of complete response (CR), CR with incomplete blood count recovery (CRi), or partial response (PR)., Up to 60 months|General Health Status/Quality of Life, Will be assessed by Questionnaire., Up to 60 months
A multicenter, prospective, single-arm clinical study of veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG) in the treatment of elderly untreated acute myeloid leukemia (AML)